Taiwan Liposome reaches full enrollment for arthritis candidate PhI/II trial.
ASLAN notches second FDA orphan designation for ASLAN001
The clinical trial landscape is witnessing an increase in Phase III trials that average more than 3,500 patients.
The opioid abuse epidemic is a thicket of particular issues. But one of the challenges of adopting alternative painkillers is more common: Price.
Drugmakers haven’t much cared for a Boston-based nonprofit’s cost-effectiveness assessments of their drugs. And now, they’re going on the offensive.
Novartis has some new Entresto data to add to its case. Researchers crunched numbers to show that the heart failure med is as cost-effective as a generic. The…
Dealing a blow to AstraZeneca in its largest FluMist Quadrivalent market, a CDC committee has stiff-armed the nasal vaccine for the upcoming season. Why? The…
Biocon and RNAi firm Quark Pharmaceuticals said the first patient has received a randomized dose in a clinical trial for ocular neuroprotection siRNA (small…
Now that Sanofi’s hostile Medivation quest has begun, the pharma giant is wondering whether it can sway investors by tossing in future payments.
Costa Rica nod the fifth approval for Sanofi's Dengvaxia
Fujifim has licensed the active pharmaceutical ingredient for flu drug Avigan to Zhejiang Hisun Pharmaceuticals.